Life After an Ischemic Stroke
An ischemic stroke happens when blood flow to part of the brain is blocked. Even after the immediate medical emergency is treated, many people continue to live with lasting effects. These may include weakness, changes in movement, trouble with coordination, speech challenges, reduced independence, and lower quality of life.
Recovery after stroke often depends on rehabilitation, time, and the brain’s ability to adapt. Physical therapy, occupational therapy, and other forms of rehab can help patients regain function, but recovery can vary widely from person to person.
Because stroke can leave long-term neurological effects, researchers are studying new ways to support healing, repair, and recovery after the initial injury.
Why Researchers Studied UC-MSCs
This study focused on umbilical cord-derived mesenchymal stem cells, often called UC-MSCs. These cells are being studied in regenerative medicine because they release signals that may influence inflammation, immune activity, blood vessel support, and tissue repair.
For stroke recovery, UC-MSCs are of interest because the brain and nervous system are highly sensitive to inflammation and reduced blood flow. Researchers want to better understand whether MSC-based therapy may help create a more supportive environment for recovery.
The goal is not to suggest that MSCs instantly repair stroke damage. Instead, this research explores whether UC-MSCs may support neurological recovery when used alongside rehabilitation.
A Study Comparing Two Delivery Methods
This was a phase II randomized controlled trial involving patients ages 40 to 75 who had lasting neurological effects after ischemic stroke.
The study compared two ways of delivering UC-MSCs:
- Intravenous infusion, or IV, which delivers cells through the bloodstream
- Intrathecal infusion, or IT, which delivers cells into the fluid-filled space around the spinal cord
A total of 32 patients received UC-MSC therapy and rehabilitation. Of these, 16 patients received IV treatment, and 16 patients received IT treatment. The study also included 16 matched control patients who received rehabilitation therapy alone.
Patients in the treatment groups received two UC-MSC infusions, spaced three months apart. The dose was 1.5 million cells per kilogram of body weight. Researchers followed patients for 12 months and checked progress at baseline, 3 months, 6 months, and 12 months.
What the Researchers Measured
To understand recovery, the researchers used several clinical tools. These looked at areas such as neurological function, independence, movement, fine motor skills, and quality of life.
In simpler terms, the study was not only asking, “Did symptoms improve?” It was also asking whether patients could function better in everyday life.
The study measured:
- Neurological impairment
- Daily independence
- Muscle stiffness and movement
- Fine motor skills
- General health and quality of life
- Brain blood flow changes using MRI
These measurements helped researchers compare the IV group, the IT group, and the rehabilitation-only control group over time.
What the Study Found
The study reported encouraging findings. No severe adverse events related to UC-MSC therapy were observed during the trial.
At 6 months, the IV group showed significant improvements in neurological scores, functional independence, and quality-of-life measurements. By 12 months, both the IV and IT groups showed significant improvements, with the IV group generally showing stronger effects in several areas.
Quality of life was one of the clearest areas of improvement. Both treatment groups improved over time, but the IV group showed larger gains compared with the control group.
The study also used brain MRI to look at blood flow changes. Some patients showed improved brain perfusion, although these MRI findings were not statistically significant. This means the imaging results were interesting, but not strong enough on their own to confirm a clear treatment effect.
Making Sense of the Results
One of the most practical parts of this study is that it compared two delivery methods. Intrathecal treatment delivers cells closer to the nervous system, while IV treatment is less invasive and delivers cells through the bloodstream.
Interestingly, the IV group showed strong results in several areas, especially by 6 and 12 months. This is important because IV delivery may be easier and more familiar in a clinical setting compared with spinal delivery.
The findings suggest that UC-MSC therapy may support recovery through cell signaling rather than direct tissue replacement. These cells may release helpful factors that support inflammation balance, blood vessel health, and communication between cells involved in healing.
Why This Research Matters
Stroke recovery can be a long and difficult process. Even with rehabilitation, many patients continue to experience limitations that affect independence and quality of life.
This study is meaningful because it explored UC-MSC therapy as an added support alongside rehabilitation. The results suggest that MSC-based therapy may have potential to improve neurological recovery and daily function in patients with lasting effects after ischemic stroke.
It also adds to a growing body of regenerative medicine research showing that MSCs may have applications beyond joint, spine, or wound-related conditions. Their ability to influence inflammation and repair signaling makes them an important area of study for neurological recovery.
What Comes Next
Although the findings are promising, more research is still needed. This was a relatively small study, and larger trials will help confirm the results, compare delivery methods more clearly, and determine which patients may benefit most.
Future research may also help clarify the best timing, dosing schedule, and delivery route for UC-MSC therapy after stroke.
Main Takeaway
This phase II clinical trial studied umbilical cord-derived MSC therapy in patients with lasting effects after ischemic stroke. Patients received UC-MSCs by either IV or intrathecal infusion along with rehabilitation, while a matched control group received rehabilitation alone.
The study found that UC-MSC therapy was not linked to severe treatment-related adverse events and was associated with improvements in neurological recovery, functional independence, and quality of life. The IV group showed especially encouraging results.
While larger studies are needed, this research highlights an important direction in regenerative medicine: using UC-MSCs to support the body’s healing environment after neurological injury and improve recovery-focused outcomes over time.
Source
Nguyen LT, Nguyen TTN, Nguyen KT, Phung LN, Hoang VT, Phan TTK, Pham MV, Nguyen ATP, Ngo DV, Nguyen AV, Nguyen CV. Intrathecal versus intravenous umbilical cord mesenchymal stem cells for ischemic stroke sequelae. Stem Cells Translational Medicine. 2025 Nov 24;14(12). doi: 10.1093/stcltm/szaf063. PMID: 41277536; PMCID: PMC12641229. https://pmc.ncbi.nlm.nih.gov/articles/PMC12641229/
Related Treatment Pages